Abstract: An application of YD1701 in preparation of a drug for treating ALDH1A3 high-expression tumor is disclosed. The YD1701 can be used as an ALDH1A3 inhibitor to reverse the occurrence of epithelial-mesenchymal transition (EMT) of ALDH1A3 high-expression cancer cells. It can reduce tumor invasion and metastasis to inhibit tumor progression and can prolong the overall survival time of tumor-bearring animals. YD1701 have low cytotoxicity.

Abstract: An injectable tissue engineered cartilage in vitro construction apparatus, comprising an incubator (1), a centrifugal device arranged in the incubator (1), and a control system for controlling a temperature in the incubator (1) and an action of the centrifugal device. The centrifugal device comprises a centrifuge, a container base (2) mounted onto the centrifuge, a dosing system for adding preparation reagent, and a stirring system for stirring the reagent. With a controller (17) and a pH sensor (16), a measured pH value will be transmitted by the pH sensor (16) to the controller (17) in real time. The controller (17) controls an action of a driving mechanism via a control module II (21), to drive a piston rod to add NaOH solution into a container tank (6). When the pH value of the solution falls in a predetermined range, the driving mechanism is stopped, to precisely control the pH value of the solution.

Abstract: The invention discloses an erythropoietin receptor modified electrode, which is a glassy carbon electrode with erythropoietin receptor as recognition element fixed onto the electrode surface via ZnO sol-gel. The modified electrode can be prepared easily, and its performance is stable. After 50-day storage in the dark at 4° C., its response current remained approximately 77% of the original value. An electrochemical biosensor using this modified electrode as working electrode, a platinum electrode as counter electrode, a saturated calomel electrode as reference electrode, and 2 mmol/L K3[Fe(CN)6]—K4[Fe(CN)6]phosphate buffer as the test base solution, can detect erythropoietin (EPO) and/or recombinant human erythropoietin (rhEPO) in a fast, specific, and sensitive manner, with a linear range of 5 pg/L-500 ng/L and a limit of detection of 0.5 pg/L. In particular, according to peak potential differences, the biosensor allows accurate discrimination of EPO and rhEPO.

Abstract: The invention discloses an erythropoietin receptor modified electrode, which is a glassy carbon electrode with erythropoietin receptor as recognition element fixed onto the electrode surface via ZnO sol-gel. The modified electrode can be prepared easily, and its performance is stable. After 50-day storage in the dark at 4° C., its response current remained approximately 77% of the original value. An electrochemical biosensor using this modified electrode as working electrode, a platinum electrode as counter electrode, a saturated calomel electrode as reference electrode, and 2 mmol/L K3[Fe(CN)6]-K4[Fe(CN)6] phosphate buffer as the test base solution, can detect erythropoietin (EPO) and/or recombinant human erythropoietin (rhEPO) in a fast, specific, and sensitive manner, with a linear range of 5 pg/L-500 ng/L and a limit of detection of 0.5 pg/L. In particular, according to peak potential differences, the biosensor allows accurate discrimination of EPO and rhEPO.